The groundbreaking discovery and development of T-1201, a novel targeting small molecule-drug conjugate (SN38), and T-1301, an innovative multi-targeted tyrosine kinase inhibitor (TKI), have been selected for an oral presentation at the prestigious 16th Annual World Cancer Congress (WCC-2024).